Stocks / Cipla (CIPLA)

CIPLA Share Price, Analysis & News

Cipla (CIPLA) — Updated on 2026-05-08

Cipla Limited operates within the biotechnology & drugs industry as a global pharmaceutical company based in India. The company's operations encompass the manufacturing, development, and marketing of a diverse portfolio of branded and generic formulations, alongside Active Pharmaceutical Ingredients (APIs). Investors closely monitor Cipla share price to understand its performance within the competitive pharmaceutical landscape. Analyzing the Cipla business model provides insight into its strategic approach to product development and market reach. Factors such as earnings reports, sector trends, and the company's fundamental performance are key considerations for those tracking its stock, particularly in relation to its position in the biotechnology and drugs sector.
Overview Daily Weekly

Key Takeaway

Cipla's stock shows recent strength despite sharp QoQ profit declines, as analysts maintain a mixed outlook on the company's fundamentals.

Daily

2026-05-08
  • The stock experienced a slight pullback of -1.12% yesterday, following a positive run over the past five days. Despite this dip, the price remains above key moving averages (9, 21, and 50-day EMAs), suggesting underlying strength and a neutral trend regime.
  • Momentum appears robust, indicated by an RSI of 64.21 and a recent bullish MACD crossover, signaling potential for upward price movement. The stock is currently trading 18.96% below its 52-week high, presenting a possible opportunity for recovery.
  • Financially, the company reported stable revenue of ₹7,074 Cr for the December 2025 quarter. However, profitability metrics showed a significant downturn, with net profit and EPS declining substantially both quarter-over-quarter and year-over-year, by approximately 50% and 57% respectively.
  • Analyst sentiment remains mixed but stable, with a combined 51.35% of analysts recommending a Buy or Strong Buy rating. This distribution has not changed significantly over the past month, indicating a consistent, albeit divided, view from market experts.
  • Institutional investors maintain a significant stake of 54.26%, with a notable shift observed this quarter. Foreign Institutional Investors (FIIs) reduced their holdings by 1.38%, while Domestic Institutional Investors (DIIs) increased theirs by 1.26%, suggesting a rotation within the institutional investor base.
Open daily analysis

Weekly

Latest weekly signal
  • The stock price rose 2.86% this week, extending a streak of five consecutive weeks of gains while maintaining a position above the 50-day moving average.
  • Short-term momentum has strengthened, with the Relative Strength Index (RSI, which measures the speed and change of price movements) rising to 64.21.
  • Cipla expanded its consumer healthcare portfolio by acquiring the distribution and marketing rights for the Endura Mass brand for 260 crore rupees.
  • The company received USFDA approval for a generic version of Ventolin HFA, a respiratory product in a market valued at approximately $1.5 billion.
  • Financial results for the quarter ended March 31, 2026, showed a consolidated net profit of 940 crore rupees, marking a 12 percent year-on-year increase.
Open weekly analysis

Quarterly

Latest quarterly update
Detailed analysis available on the full page.

Price & Technical Structure

  • The stock experienced a short-term decline of -1.12% in the last day, following a positive 2.86% return over the past 5 days.
  • The trend regime is neutral, with the price trading above the 9, 21, and 50-day EMAs, and is 3.76% above the 50-day moving average.
  • Momentum is strong, indicated by an RSI of 64.21 and a bullish MACD crossover.
  • Volatility is moderate, with the price positioned at 81.7% of the Bollinger Band width, which is 16.1%.
  • The stock is trading 18.96% below its 52-week high and 13.07% above its 52-week low, with a current drawdown of -18.96%.
The stock exhibits a neutral trend with positive short-term momentum, as evidenced by its position above key EMAs and a bullish MACD signal. While volatility is present, the price is within the Bollinger Bands, suggesting room for movement. The stock is positioned significantly below its 52-week high, indicating potential for recovery, but also shows a notable drawdown.

Weekly Momentum

  • The stock price rose 2.86% this week, extending a streak of five consecutive weeks of gains while maintaining a position above the 50-day moving average.
  • Short-term momentum has strengthened, with the Relative Strength Index (RSI, which measures the speed and change of price movements) rising to 64.21.
  • Cipla expanded its consumer healthcare portfolio by acquiring the distribution and marketing rights for the Endura Mass brand for 260 crore rupees.
  • The company received USFDA approval for a generic version of Ventolin HFA, a respiratory product in a market valued at approximately $1.5 billion.
  • Financial results for the quarter ended March 31, 2026, showed a consolidated net profit of 940 crore rupees, marking a 12 percent year-on-year increase.
Cipla experienced a week of positive price momentum and strategic growth. The stock price continued its upward trend, supported by strengthening short-term momentum indicators like the RSI and MACD. This market optimism aligns with recent corporate developments, including the acquisition of the Endura Mass brand and USFDA approval for a key generic respiratory product. Furthermore, the company reported a 12 percent year-on-year increase in net profit for the quarter ended March 31, 2026, providing a fundamental basis for the recent price appreciation.